Geoffrey Y. Ku, MD

Geoffrey Y. Ku, MD, discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.

Geoffrey Y. Ku, MD, breaks down HER2-targeted and MSI-high perioperative strategies in gastroesophageal cancer, including new PHERFLOT trial data.

Geoffrey Y. Ku, MD, discusses MATTERHORN, which established perioperative durvalumab plus FLOT as standard care for resectable gastric/GEJ adenocarcinoma.

Geoffrey Y. Ku, MD, explains the latest developments with bispecific antibodies in patients with gastric and gastroesophageal junction cancers.

Geoffrey Y. Ku, MD, highlights ongoing advances in gastric/GEJ treatment.

Geoffrey Y. Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers.

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.